Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Ray, KK; Aguiar, C; Arca, M; Connolly, DL; Eriksson, M; Ferrières, J; Laufs, U; Mostaza, JM; Nanchen, D; Bardet, A; Lamparter, M; Chhabra, R; Soronen, J; Rietzschel, E; Strandberg, T; Toplak, H; Visseren, FLJ; Catapano, AL.
Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study.
Eur J Prev Cardiol. 2024; Doi: 10.1093/eurjpc/zwae199
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Toplak Hermann

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

AIM: To assess whether implementation of the 2019 ESC/EAS dyslipidaemia guidelines observed between 2020-2021 improved between 2021-2022 in the SANTORINI study. METHODS: High- or very-high cardiovascular (CV) risk patients were recruited across 14 European countries from March 2020-February 2021, with 1-year prospective follow-up until May 2022. Lipid-lowering therapy (LLT) and 2019 ESC/EAS risk-based low-density lipoprotein cholesterol (LDL-C) goal attainment (defined as <1.4 mmol/L for patients at very high CV risk and <1.8 mmol/L for patients at high CV risk) at 1-year follow-up were compared with baseline. . RESULTS: Of 9559 patients enrolled, 9136 (2626 high risk, 6504 very high risk) had any follow-up data, and 7210 (2033 high risk, 5173 very high risk) had baseline and follow-up LDL-C data. LLT was escalated in one-third of patients and unchanged in two-thirds. Monotherapy and combination therapy usage rose from 53.6% and 25.6% to 57.1% and 37.9%, respectively. Mean LDL-C levels decreased from 2.4 mmol/L to 2.0 mmol/L. Goal attainment improved from 21.2% to 30.9%, largely driven by LLT use among those not on LLT at baseline. Goal attainment was greater with combination therapy compared with monotherapy at follow-up (39.4 vs 25.5%). CONCLUSIONS: LLT use and achievement of risk-based lipid goals increased over 1-year follow-up particularly when combination LLT was used. Nonetheless, most patients remained above goal, hence strategies are needed to improve implementation of combination LLT.

Find related publications in this database (Keywords)

Real-world clinical trials

Lipid

Dyslipidaemia

Europe

Cardiovascular risk

© Med Uni Graz • Imprint